Tumor Mutational Burden as a Predictor of Survival With Durvalumab and/or Tremelimumab in Patients With Recurrent or Metastatic HNSCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Tumor Mutational Burden as a Predictor of Survival With Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Clin. Cancer Res 2023 Feb 20;[EPub Ahead of Print], S Wildsmith, W Li, S Wu, R Stewart, N Morsli, R Raja, Q Zhang, J Ye, P He, J Shetty, A Yovine, N Holoweckyj, K Real, J Walker, M Wrona, M de Los Reyes, C Barker, J Whiteley, R Haddad, L Licitra, R Ferris, J Fayette, DP Zandberg, LL Siu, R MesíaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.